Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Recommendations for the Use of Audit and Feedback to De-Implement Low-Value Care.

Whittington MD, Ho PM, Helfrich CD.

Am J Med Qual. 2019 Jan 17:1062860618824153. doi: 10.1177/1062860618824153. [Epub ahead of print] No abstract available.

PMID:
30654620
2.

UK survey of non-medical use of prescription drugs (NMURx) as a valuable source of general population illicit drug use data.

Ng FL, Rockhill K, Black J, May KP, Whittington MD, Wood DM, Dargan PI, Green JL.

Postgrad Med J. 2018 Nov;94(1117):627-633. doi: 10.1136/postgradmedj-2018-135798.

PMID:
30635430
3.

Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis.

Whittington MD, McQueen RB, Ollendorf DA, Chapman RH, Kumar VM, Synnott PG, Agboola F, Campbell JD.

J Manag Care Spec Pharm. 2019 Jan;25(1):80-87. doi: 10.18553/jmcp.2019.25.1.080.

4.

Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy.

Whittington MD, Ollendorf DA, Campbell JD.

JAMA Oncol. 2018 Dec 1;4(12):1784-1785. doi: 10.1001/jamaoncol.2018.4625. No abstract available.

PMID:
30325984
5.

Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia.

Whittington MD, McQueen RB, Ollendorf DA, Kumar VM, Chapman RH, Tice JA, Pearson SD, Campbell JD.

JAMA Pediatr. 2018 Dec 1;172(12):1161-1168. doi: 10.1001/jamapediatrics.2018.2530.

PMID:
30304407
6.

Prices For Common Cardiovascular Drugs In The US Are Not Consistently Aligned With Value.

Campbell JD, Belozeroff V, Whittington MD, Rubin RJ, Raggi P, Briggs AH.

Health Aff (Millwood). 2018 Aug;37(8):1298-1305. doi: 10.1377/hlthaff.2018.0221.

PMID:
30080450
7.

RCT of Centralized Vaccine Reminder/Recall for Adults.

Hurley LP, Beaty B, Lockhart S, Gurfinkel D, Breslin K, Dickinson M, Whittington MD, Roth H, Kempe A.

Am J Prev Med. 2018 Aug;55(2):231-239. doi: 10.1016/j.amepre.2018.04.022. Epub 2018 Jun 15.

PMID:
29910118
8.

Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations.

McQueen RB, Sheehan DN, Whittington MD, van Boven JFM, Campbell JD.

Pharmacoeconomics. 2018 Aug;36(8):957-971. doi: 10.1007/s40273-018-0658-x. Review.

PMID:
29736895
9.

Achieving high value care for all and the perverse incentives of 340B price agreements.

Whittington MD, Campbell JD, McQueen RB.

Neurol Clin Pract. 2018 Apr;8(2):148-152. doi: 10.1212/CPJ.0000000000000437.

10.

Economic Value of Improved Accuracy for Self-Monitoring of Blood Glucose Devices for Type 1 and Type 2 Diabetes in England.

McQueen RB, Breton MD, Craig J, Holmes H, Whittington MD, Ott MA, Campbell JD.

J Diabetes Sci Technol. 2018 Sep;12(5):992-1001. doi: 10.1177/1932296818769098. Epub 2018 Apr 21.

PMID:
29681171
11.

Considerations for Cost-effectiveness Analysis of Curative Pediatric Therapies.

Whittington MD, McQueen RB, Campbell JD.

JAMA Pediatr. 2018 May 1;172(5):409-410. doi: 10.1001/jamapediatrics.2018.0049. No abstract available.

PMID:
29554182
12.

Assessing the impact of caring for a child with Dravet syndrome: Results of a caregiver survey.

Campbell JD, Whittington MD, Kim CH, VanderVeen GR, Knupp KG, Gammaitoni A.

Epilepsy Behav. 2018 Mar;80:152-156. doi: 10.1016/j.yebeh.2018.01.003. Epub 2018 Feb 2.

13.

The direct and indirect costs of Dravet Syndrome.

Whittington MD, Knupp KG, Vanderveen G, Kim C, Gammaitoni A, Campbell JD.

Epilepsy Behav. 2018 Mar;80:109-113. doi: 10.1016/j.yebeh.2017.12.034. Epub 2018 Feb 2.

PMID:
29414539
14.

Value of Public Health Funding in Preventing Hospital Bloodstream Infections in the United States.

Whittington MD, Bradley CJ, Atherly AJ, Campbell JD, Lindrooth RC.

Am J Public Health. 2017 Nov;107(11):1764-1769. doi: 10.2105/AJPH.2017.303987. Epub 2017 Sep 21.

PMID:
28933936
15.

Recommendations for Methicillin-Resistant Staphylococcus aureus Prevention in Adult ICUs: A Cost-Effectiveness Analysis.

Whittington MD, Atherly AJ, Curtis DJ, Lindrooth RC, Bradley CJ, Campbell JD.

Crit Care Med. 2017 Aug;45(8):1304-1310. doi: 10.1097/CCM.0000000000002484.

PMID:
28471887
16.

Impact of Nonmedical Vaccine Exemption Policies on the Health and Economic Burden of Measles.

Whittington MD, Kempe A, Dempsey A, Herlihy R, Campbell JD.

Acad Pediatr. 2017 Jul;17(5):571-576. doi: 10.1016/j.acap.2017.03.001. Epub 2017 Mar 9.

PMID:
28286295
17.

Screening test recommendations for methicillin-resistant Staphylococcus aureus surveillance practices: A cost-minimization analysis.

Whittington MD, Curtis DJ, Atherly AJ, Bradley CJ, Lindrooth RC, Campbell JD.

Am J Infect Control. 2017 Jul 1;45(7):704-708. doi: 10.1016/j.ajic.2016.12.014. Epub 2017 Jan 23.

PMID:
28126259
18.

Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.

Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD, Campbell JD.

Ann Allergy Asthma Immunol. 2017 Feb;118(2):220-225. doi: 10.1016/j.anai.2016.10.028. Epub 2016 Dec 4.

PMID:
27923549
19.

A Primer on Health Economic Evaluations in Thoracic Oncology.

Whittington MD, Atherly AJ, Bocsi GT, Camidge DR.

J Thorac Oncol. 2016 Aug;11(8):1224-1232. doi: 10.1016/j.jtho.2016.04.004. Epub 2016 Apr 12. Review.

Supplemental Content

Loading ...
Support Center